P

Plus Therapeutics

D
PSTV
USD
-0.11
(-8.0882%)
Market Open
404.00
Volume
-2.22
EPS
-
Div Yield
-0.404531
P/E
7,370,416.25
Market Cap
Today
-8.0882%
1 Week
-3.101%
1 Month
-11.348%
6 Months
-40.758%
12 Months
-24.699%
Year To Date
-28.576%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
AMC
-0.085
(-1.979%)
USD
C
CNK
0.01
(0.0317%)
USD
I
IMAX
-0.44
(-1.7807%)
USD
NFLX
NFLX
-3.08
(-0.3866%)
USD
DIS
DIS
0.09
(0.091%)
USD
CMCSA
CMCSA
-0.26
(-0.5888%)
USD
T
T
0.335
(1.5193%)
USD
F
FOXA
0.1
(0.224%)
USD

Title:
Plus Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Do you need help or have a question?
Contact Us